as 11-05-2024 10:36am EST
Stocks
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.
Founded: | 2009 | Country: | United States |
Employees: | N/A | City: | SAN DIEGO |
Market Cap: | 193.8M | IPO Year: | N/A |
Target Price: | N/A | AVG Volume (30 days): | 94.4K |
Analyst Decision: | N/A | Number of Analysts: | N/A |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -0.43 | EPS Growth: | N/A |
52 Week Low/High: | $2.83 - $23.73 | Next Earning Date: | 11-15-2024 |
Revenue: | N/A | Revenue Growth: | N/A |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
HURA Breaking Stock News: Dive into HURA Ticker-Specific Updates for Smart Investing
ACCESSWIRE
13 days ago
ACCESSWIRE
14 days ago
The information presented on this page, "HURA TuHURA Biosciences Inc. Common Stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.